Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settingsGAVRETO generated ~$28M in U.S. net product sales in 2023SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (NASDAQ:RIGL) today announced that it has entered into a definitive agreement to acquire the U.S. rights to GAVRETO® (pralsetinib) from Blueprint Medicines Corporation ("Blueprint"). GAVRET
